data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
Watch
YouTube
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Citius Pharmaceuticals
(NASDAQ:CTXR)
Citius Pharmaceuticals, Inc. - Common Stock is expected to split Monday, August 15, 2022 with a ratio of 1:5
Citius Pharmaceuticals, Inc. - Common Stock recently split on Friday, August 12, 2022 with a ratio of 1:3
$1.17
-0.02[-1.68%]
At close: Aug 12
$1.20
0.0300[2.56%]
After Hours: 6:02PM EDT
Day High/Low1.08 - 1.22
52 Week High/Low0.83 - 2.01
Open / Close1.13 / 1.17
Float / Outstanding133.8M / 146.1M
Vol / Avg.1.1M / 1.2M
Mkt Cap171M
P/E-
50d Avg. Price0.95
Div / Yield-
Payout Ratio-
EPS-0.05
Total Float133.8M

Citius Pharmaceuticals (NASDAQ:CTXR), Quotes and News Summary

Citius Pharmaceuticals (NASDAQ: CTXR)

Day High/Low1.08 - 1.22
52 Week High/Low0.83 - 2.01
Open / Close1.13 / 1.17
Float / Outstanding133.8M / 146.1M
Vol / Avg.1.1M / 1.2M
Mkt Cap171M
P/E-
50d Avg. Price0.95
Div / Yield-
Payout Ratio-
EPS-0.05
Total Float133.8M
Sector: Health Care.Industry: Pharmaceuticals
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Read More

Earnings

see more
FY 2023Est.ActualSurprise
EPS
(EXPECTED)2023-12-20
REV
FY 2023Est.ActualSurprise
EPS
(EXPECTED)2023-11-09
REV

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Citius Pharmaceuticals Questions & Answers

Q
How do I buy Citius Pharmaceuticals (CTXR) stock?
A

You can purchase shares of Citius Pharmaceuticals (NASDAQ: CTXR) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Citius Pharmaceuticals's (CTXR) competitors?
Q
What is the target price for Citius Pharmaceuticals (CTXR) stock?
A

The latest price target for Citius Pharmaceuticals (NASDAQ: CTXR) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting CTXR to rise to within 12 months (a possible 241.88% upside). 50 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Citius Pharmaceuticals (CTXR)?
A

The stock price for Citius Pharmaceuticals (NASDAQ: CTXR) is $1.17 last updated August 12, 2022, 8:00 PM UTC.

Q
Does Citius Pharmaceuticals (CTXR) pay a dividend?
A

The next Citius Pharmaceuticals (CTXR) dividend date is projected to be Thursday, September 1, 2022.

Q
When is Citius Pharmaceuticals (NASDAQ:CTXR) reporting earnings?
A

Citius Pharmaceuticals’s FY earnings are confirmed for Wednesday, December 20, 2023.

Q
Is Citius Pharmaceuticals (CTXR) going to split?
A

There is no upcoming split for Citius Pharmaceuticals.

Q
What sector and industry does Citius Pharmaceuticals (CTXR) operate in?
A

Citius Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.